The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
Abstract
Purpose: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy that is characterized by features of both a myeloproliferative neoplasm and a myelodysplastic syndrome. Thus far, data on a comprehensive cytogenetic or molecular genetic characterization are limited. Patients and Methods: Here, we analyzed 81 thoroughly characterized patients with CMML (CMML type 1, n = 45; CMML type 2, n = 36) by applying next-generation sequencing (NGS) technology to investigate CBL, JAK2, MPL, NRAS, and KRAS at known mutational hotspot regions. In addition, complete coding regions were analyzed for RUNX1 (β isoform) and TET2 aberrations. Results: Cytogenetic aberrations were found in 18.2% of patients (14 of 77 patients). In contrast, at least one molecular mutation was observed in 72.8% of patients (59 of 81 patients). A mean of 1.6 mutations per patient was observed by this unprecedented screening. In total, 105 variances were detected by this comprehensive molecular screening. After excluding known polymorphisms or silent mutations, 82 distinct mutations remained (CBL, n = 15; JAK2V617F, n = 8; MPL, n = 0; NRAS, n = 10; KRAS, n = 12; RUNX1, n = 7; and TET2, n = 41). With respect to clinical data, a better outcome was seen for patients carrying TET2 mutations (P = .013). Conclusion: The number of molecular markers used to categorize myeloid neoplasms is constantly increasing. Here, NGS screening has been demonstrated to support a comprehensive characterization of the molecular background in CMML. A pattern of molecular mutations translates into different biologic and prognostic categories of CMML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Genome sequencing in microfabricated high-density picolitre reactors
Margulies, M., Egholm, M., Altman, W. E., Attiya, S., Bader, J. S., Bemben, L. A., Berka, J., Braverman, M. S., Chen, Y.-J., Chen, Z., et al. (2005) · Nature · doi:10.1038/nature03959 · Cited by 7,693
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Next-Generation Sequencing: From Basic Research to Diagnostics
Voelkerding, K. V., Dames, S. A., & Durtschi, J. D. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112789 · Cited by 839
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Acquired mutations in TET2 are common in myelodysplastic syndromes
Langemeijer, S. M. C., Kuiper, R. P., Berends, M., Knops, R., Aslanyan, M. G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A. G., Raymakers, R. A. P., et al. (2009) · Nature Genetics · doi:10.1038/ng.391 · Cited by 680
Tefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Onida, F., Kantarjian, H. M., Smith, T. L., Ball, G., Keating, M. J., Estey, E. H., Glassman, A. B., Albitar, M., Kwari, M. I., & Beran, M. (2002) · Blood · doi:10.1182/blood.v99.3.840 · Cited by 385
Grand, F. H., Hidalgo-Curtis, C. E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., Kreil, S., Jones, A., Score, J., Metzgeroth, G., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194548 · Cited by 378
Thomas, R. K., Nickerson, E., Simons, J. F., Jänne, P. A., Tengs, T., Yuza, Y., Garraway, L. A., LaFramboise, T., Lee, J. C., Shah, K., et al. (2006) · Nature Medicine · doi:10.1038/nm1437 · Cited by 361
Jankowska, A. M., Szpurka, H., Tiu, R. V., Makishima, H., Afable, M., Huh, J., O'Keefe, C. L., Ganetzky, R., McDevitt, M. A., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2009-02-205690 · Cited by 331
Dunbar, A. J., Gondek, L. P., O'Keefe, C. L., Makishima, H., Rataul, M. S., Szpurka, H., Sekeres, M. A., Wang, X. F., McDevitt, M. A., & Maciejewski, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2754 · Cited by 299
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215814 · Cited by 276
Tefferi, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Patnaik, M. M., Hanson, C. A., Pardanani, A., Gilliland, D. G., & Levine, R. L. (2009) · Leukemia · doi:10.1038/leu.2009.59 · Cited by 268
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
Tefferi, A., Levine, R. L., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Finke, C. M., Mullally, A., Li, C.-Y., Pardanani, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.37 · Cited by 252
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N., Quesnel, B., Fenaux, P., Bastie, J.-N., Beyne-Rauzy, O., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.011205 · Cited by 247
Bacher, U., Haferlach, T., Kern, W., Haferlach, C., & Schnittger, S. (2007) · Haematologica · doi:10.3324/haematol.10869 · Cited by 164
Self-citationGenome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes
Gelsi‐Boyer, V., Trouplin, V., Adélaïde, J., Aceto, N., Rémy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires‐Alj, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-299 · Cited by 147
Tyner, J. W., Erickson, H., Deininger, M. W., Willis, S. G., Eide, C. A., Levine, R. L., Heinrich, M. C., Gattermann, N., Gilliland, D. G., Druker, B. J., et al. (2008) · Blood · doi:10.1182/blood-2008-04-152157 · Cited by 137
Risk Assessment in Chronic Myelomonocytic Leukemia (CMML)
Germing, U., Kündgen, A., & Gattermann, N. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819042000207271 · Cited by 135
Chronic myelomonocytic leukemia in the light of the WHO proposals
Germing, U., Strupp, C., Knipp, S., Kuendgen, A., Giagounidis, A. A. N., Hildebrandt, B., Aul, C., Haas, R., Gattermann, N., & Bennett, J. M. (2007) · Haematologica · doi:10.3324/haematol.11051 · Cited by 74
Beran, M., Wen, S., Shen, Y., Onida, F., Jelı́nek, J., Cortes, J. E., Giles, F. J., & Kantarjian, H. M. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701216386 · Cited by 69
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
Feldman, E. J., Cortes, J. E., DeAngelo, D. J., Holyoake, T. L., Simonsson, B., O'Brien, S. G., Reiffers, J. J., Turner, A. R., Roboz, G. J., Lipton, J. H., et al. (2008) · Leukemia · doi:10.1038/leu.2008.156 · Cited by 65
Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias
Couronné, L., Lippert, É., Andrieux, J., Kosmider, O., Radford‐Weiss, I., Penther, D., Dastugue, N., Mugneret, F., Lafage‐Pochitaloff, M., Gachard, N., et al. (2009) · Leukemia · doi:10.1038/leu.2009.169 · Cited by 55
Karp, J. E., Flatten, K. S., Feldman, E. J., Greer, J. M., Loegering, D. A., Ricklis, R. M., Morris, L. E., Ritchie, E. K., Smith, B. D., Ironside, V., et al. (2008) · Blood · doi:10.1182/blood-2008-08-172726 · Cited by 53
Cited by
Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3314 · Cited by 545
Self-citationRET revisited: expanding the oncogenic portfolio
Mulligan, L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3680 · Cited by 513
Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation
Hu, L., Li, Z., Cheng, J., Rao, Q., Gong, W., Liu, M., Shi, Y. G., Zhu, J., Wang, P., & Xu, Y. (2013) · Cell · doi:10.1016/j.cell.2013.11.020 · Cited by 450
Rampal, R., Al-Shahrour, F., Abdel-Wahab, O., Patel, J. P., Brunel, J.-P., Mermel, C. H., Bass, A. J., Pretz, J., Ahn, J., Hricik, T., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554634 · Cited by 428
Metadata
- Authors
- Kohlmann, A., Grossmann, V., Klein, H.-U., Schindela, S., Weiss, T., Kazak, B., Dicker, F., Schnittger, S., Dugas, M., Kern, W., Haferlach, C., & Haferlach, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-08-20
- Volume
- 28
- Issue
- 24
- Pages
- 3858-3865
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2127332345
- Cited by
- 299
- References
- 27
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.